Table 2.
Treatment modifications
| FAS population | |
|---|---|
| Dose interruptionsa: n (%) | 204 (31.2) |
| Reasons: n (%) | |
| Patient willingness | 8 (3.9) |
| General health deterioration | 29 (14.2) |
| Adverse event (treatment-related or not) | 173 (84.8) |
| Other | 9 (4.4) |
| Dose reduction: n (%) | 278 (42.5) |
| Reasons: n (%) | |
| Patient willingness | 6 (2.2) |
| General health deterioration | 66 (23.7) |
| Disease progression | 2 (0.7) |
| Adverse event (treatment-related or not) | 226 (81.3) |
| Other | 20 (7.2) |
| Any kind of dose modification: n (%) | 329 (50.3) |
aPermanent or temporary interruption